Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.

Ligand binding to receptor tyrosine kinases (RTKs) regulates receptor dimerization and activation of the kinase domain. To examine the role of the transmembrane domain in regulation of RTK activation, we have exploited a simplified transmembrane motif, [VVVEVVV](n), previously shown to activate the Neu receptor. Here we demonstrate rotational linkage of the transmembrane domain with the kinase domain, as evidenced by a periodic activation of Neu as the dimerization motif is shifted across the transmembrane domain. These results indicate that activation requires a specific orientation of the kinase domains with respect to each other. Results obtained with platelet-derived growth factor receptor-beta suggest that this rotational linkage of the transmembrane domain to the kinase domain may be a general feature of RTKs. These observations suggest that activating mutations in RTK transmembrane and juxtamembrane domains will be limited to those residues that position the kinase domains in an allowed rotational conformation.

[1]  C. Marshall,et al.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.

[2]  I. Wilson,et al.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.

[3]  Wen He,et al.  An antagonist peptide–EPO receptor complex suggests that receptor dimerization is not sufficient for activation , 1998, Nature Structural Biology.

[4]  D. Stern,et al.  Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer Interface , 1998, Molecular and Cellular Biology.

[5]  Arthur Weiss,et al.  Switching Signals On or Off by Receptor Dimerization , 1998, Cell.

[6]  L S Mulcahy,et al.  Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. , 1998, Biochemistry.

[7]  D. DiMaio,et al.  Oncogenic activation of the PDGF β receptor by the transmembrane domain of p185neu* , 1998, Oncogene.

[8]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[9]  M. Moran,et al.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.

[10]  A. N. Meyer,et al.  Transmembrane Domain Sequence Requirements for Activation of the p185c-neu Receptor Tyrosine Kinase , 1997, The Journal of cell biology.

[11]  D. Donoghue,et al.  FGFR activation in skeletal disorders: too much of a good thing. , 1997, Trends in genetics : TIG.

[12]  D. Engelman,et al.  Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation , 1997, Oncogene.

[13]  A. Ullrich,et al.  Novel mechanisms of RTK signal generation. , 1997, Current opinion in genetics & development.

[14]  Enrico A. Stura,et al.  Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å , 1996, Science.

[15]  A. N. Meyer,et al.  Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[17]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[18]  B. Bormann,et al.  Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor , 1996, Nature Structural Biology.

[19]  D. Donoghue,et al.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.

[20]  I. Munro,et al.  Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans , 1995, Nature Genetics.

[21]  K. Shokat.  Tyrosine kinases: modular signaling enzymes with tunable specificities. , 1995, Chemistry & biology.

[22]  M. Hung,et al.  Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. , 1995, Oncogene.

[23]  L. Williams,et al.  Binding of NCK to SOS and activation of ras-dependent gene expression , 1995, Molecular and cellular biology.

[24]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[25]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[26]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[27]  W. Dougall,et al.  Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. , 1995, Oncogene.

[28]  D. Baltimore,et al.  SH2 and SH3 domains as molecular adhesives: the interactions of Crk and Abl. , 1994, Trends in biochemical sciences.

[29]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[30]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[31]  M. Karin,et al.  c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK , 1994, Nature.

[32]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[33]  A. Ullrich,et al.  Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond. , 1994, The Journal of biological chemistry.

[34]  T. Pawson,et al.  Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction. , 1994, Trends in genetics : TIG.

[35]  B. Bormann,et al.  A subdomain in the transmembrane domain is necessary for p185neu* activation. , 1992, The EMBO journal.

[36]  D. Mulvey,et al.  Three dimensional structure of the transmembrane region of the proto‐oncogenic and oncogenic forms of the neu protein. , 1992, The EMBO journal.

[37]  C. Molloy,et al.  The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency , 1991, Molecular and cellular biology.

[38]  S. Rackovsky,et al.  Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[40]  M. Sternberg,et al.  A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. , 1990, Protein engineering.

[41]  W. Gullick,et al.  Neu receptor dimerization , 1989, Nature.

[42]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[43]  Cori Bargmann,et al.  Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Cori Bargmann,et al.  Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.

[45]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[46]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[47]  A. Ullrich,et al.  Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.

[48]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[49]  A. N. Meyer,et al.  Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[50]  D Cowburn,et al.  Modular peptide recognition domains in eukaryotic signaling. , 1997, Annual review of biophysics and biomolecular structure.

[51]  C. Heldin.  Protein tyrosine kinase receptors. , 1996, Cancer surveys.

[52]  W. Fantl,et al.  Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.

[53]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[54]  S. Coughlin,et al.  Signal transduction by the platelet-derived growth factor receptor. , 1988, Cold Spring Harbor symposia on quantitative biology.